|
Gene: NDUFB10 |
Gene summary for NDUFB10 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NDUFB10 | Gene ID | 4716 |
Gene name | NADH:ubiquinone oxidoreductase subunit B10 | |
Gene Alias | MC1DN35 | |
Cytomap | 16p13.3 | |
Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | A8K761 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4716 | NDUFB10 | GSM4909286 | Human | Breast | IDC | 1.71e-03 | -2.50e-01 | 0.1081 |
4716 | NDUFB10 | GSM4909287 | Human | Breast | IDC | 2.33e-08 | 4.03e-01 | 0.2057 |
4716 | NDUFB10 | GSM4909291 | Human | Breast | IDC | 2.09e-03 | 3.44e-01 | 0.1753 |
4716 | NDUFB10 | GSM4909293 | Human | Breast | IDC | 1.03e-12 | 4.15e-01 | 0.1581 |
4716 | NDUFB10 | GSM4909294 | Human | Breast | IDC | 5.45e-16 | 3.29e-01 | 0.2022 |
4716 | NDUFB10 | GSM4909296 | Human | Breast | IDC | 4.45e-12 | 1.08e-01 | 0.1524 |
4716 | NDUFB10 | GSM4909297 | Human | Breast | IDC | 1.08e-16 | 9.37e-03 | 0.1517 |
4716 | NDUFB10 | GSM4909298 | Human | Breast | IDC | 6.65e-10 | 4.06e-01 | 0.1551 |
4716 | NDUFB10 | GSM4909301 | Human | Breast | IDC | 2.60e-10 | 3.04e-01 | 0.1577 |
4716 | NDUFB10 | GSM4909302 | Human | Breast | IDC | 2.67e-03 | 2.35e-01 | 0.1545 |
4716 | NDUFB10 | GSM4909304 | Human | Breast | IDC | 7.28e-28 | 5.62e-01 | 0.1636 |
4716 | NDUFB10 | GSM4909305 | Human | Breast | IDC | 7.77e-03 | 3.05e-01 | 0.0436 |
4716 | NDUFB10 | GSM4909306 | Human | Breast | IDC | 3.90e-40 | 7.09e-01 | 0.1564 |
4716 | NDUFB10 | GSM4909307 | Human | Breast | IDC | 5.59e-15 | 4.24e-01 | 0.1569 |
4716 | NDUFB10 | GSM4909308 | Human | Breast | IDC | 4.76e-19 | 5.26e-01 | 0.158 |
4716 | NDUFB10 | GSM4909311 | Human | Breast | IDC | 7.51e-42 | -1.48e-01 | 0.1534 |
4716 | NDUFB10 | GSM4909312 | Human | Breast | IDC | 4.61e-10 | -2.82e-02 | 0.1552 |
4716 | NDUFB10 | GSM4909313 | Human | Breast | IDC | 1.24e-02 | 1.66e-01 | 0.0391 |
4716 | NDUFB10 | GSM4909317 | Human | Breast | IDC | 4.64e-16 | 5.20e-01 | 0.1355 |
4716 | NDUFB10 | GSM4909318 | Human | Breast | IDC | 1.18e-13 | 6.45e-01 | 0.2031 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00460349 | Breast | Precancer | ATP metabolic process | 82/1080 | 277/18723 | 1.94e-36 | 5.19e-33 | 82 |
GO:00061199 | Breast | Precancer | oxidative phosphorylation | 53/1080 | 141/18723 | 1.15e-29 | 2.04e-26 | 53 |
GO:00090608 | Breast | Precancer | aerobic respiration | 58/1080 | 189/18723 | 5.69e-27 | 7.62e-24 | 58 |
GO:00060918 | Breast | Precancer | generation of precursor metabolites and energy | 94/1080 | 490/18723 | 1.54e-25 | 1.64e-22 | 94 |
GO:00453338 | Breast | Precancer | cellular respiration | 59/1080 | 230/18723 | 5.97e-23 | 5.32e-20 | 59 |
GO:00159808 | Breast | Precancer | energy derivation by oxidation of organic compounds | 70/1080 | 318/18723 | 8.33e-23 | 6.37e-20 | 70 |
GO:00196468 | Breast | Precancer | aerobic electron transport chain | 34/1080 | 87/18723 | 3.95e-20 | 2.64e-17 | 34 |
GO:00427738 | Breast | Precancer | ATP synthesis coupled electron transport | 35/1080 | 95/18723 | 1.08e-19 | 5.76e-17 | 35 |
GO:00427758 | Breast | Precancer | mitochondrial ATP synthesis coupled electron transport | 35/1080 | 95/18723 | 1.08e-19 | 5.76e-17 | 35 |
GO:00229048 | Breast | Precancer | respiratory electron transport chain | 35/1080 | 114/18723 | 8.51e-17 | 3.26e-14 | 35 |
GO:00229008 | Breast | Precancer | electron transport chain | 42/1080 | 175/18723 | 1.37e-15 | 4.59e-13 | 42 |
GO:00061208 | Breast | Precancer | mitochondrial electron transport, NADH to ubiquinone | 19/1080 | 51/18723 | 2.05e-11 | 2.49e-09 | 19 |
GO:00102578 | Breast | Precancer | NADH dehydrogenase complex assembly | 19/1080 | 57/18723 | 1.93e-10 | 1.92e-08 | 19 |
GO:00329818 | Breast | Precancer | mitochondrial respiratory chain complex I assembly | 19/1080 | 57/18723 | 1.93e-10 | 1.92e-08 | 19 |
GO:00331088 | Breast | Precancer | mitochondrial respiratory chain complex assembly | 24/1080 | 93/18723 | 3.39e-10 | 3.16e-08 | 24 |
GO:004603414 | Breast | IDC | ATP metabolic process | 85/1434 | 277/18723 | 6.42e-30 | 1.82e-26 | 85 |
GO:000611913 | Breast | IDC | oxidative phosphorylation | 56/1434 | 141/18723 | 1.87e-26 | 3.53e-23 | 56 |
GO:000906013 | Breast | IDC | aerobic respiration | 61/1434 | 189/18723 | 4.42e-23 | 6.27e-20 | 61 |
GO:000609113 | Breast | IDC | generation of precursor metabolites and energy | 103/1434 | 490/18723 | 1.53e-21 | 1.74e-18 | 103 |
GO:004533313 | Breast | IDC | cellular respiration | 62/1434 | 230/18723 | 5.98e-19 | 4.25e-16 | 62 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0493220 | Endometrium | AEH | Non-alcoholic fatty liver disease | 67/1197 | 155/8465 | 5.91e-19 | 1.75e-17 | 1.28e-17 | 67 |
hsa0471426 | Endometrium | AEH | Thermogenesis | 85/1197 | 232/8465 | 3.44e-18 | 9.33e-17 | 6.83e-17 | 85 |
hsa0502220 | Endometrium | AEH | Pathways of neurodegeneration - multiple diseases | 137/1197 | 476/8465 | 9.27e-18 | 2.32e-16 | 1.70e-16 | 137 |
hsa0472320 | Endometrium | AEH | Retrograde endocannabinoid signaling | 39/1197 | 148/8465 | 5.89e-05 | 5.80e-04 | 4.24e-04 | 39 |
hsa05012111 | Endometrium | AEH | Parkinson disease | 115/1197 | 266/8465 | 6.24e-32 | 1.01e-29 | 7.42e-30 | 115 |
hsa05020110 | Endometrium | AEH | Prion disease | 110/1197 | 273/8465 | 2.39e-27 | 2.44e-25 | 1.78e-25 | 110 |
hsa05016110 | Endometrium | AEH | Huntington disease | 118/1197 | 306/8465 | 3.00e-27 | 2.44e-25 | 1.78e-25 | 118 |
hsa00190110 | Endometrium | AEH | Oxidative phosphorylation | 69/1197 | 134/8465 | 5.80e-25 | 3.14e-23 | 2.30e-23 | 69 |
hsa05415111 | Endometrium | AEH | Diabetic cardiomyopathy | 86/1197 | 203/8465 | 2.62e-23 | 1.22e-21 | 8.90e-22 | 86 |
hsa05208112 | Endometrium | AEH | Chemical carcinogenesis - reactive oxygen species | 91/1197 | 223/8465 | 3.28e-23 | 1.33e-21 | 9.76e-22 | 91 |
hsa05014110 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
hsa05010110 | Endometrium | AEH | Alzheimer disease | 124/1197 | 384/8465 | 1.20e-20 | 3.91e-19 | 2.86e-19 | 124 |
hsa04932110 | Endometrium | AEH | Non-alcoholic fatty liver disease | 67/1197 | 155/8465 | 5.91e-19 | 1.75e-17 | 1.28e-17 | 67 |
hsa04714111 | Endometrium | AEH | Thermogenesis | 85/1197 | 232/8465 | 3.44e-18 | 9.33e-17 | 6.83e-17 | 85 |
hsa05022110 | Endometrium | AEH | Pathways of neurodegeneration - multiple diseases | 137/1197 | 476/8465 | 9.27e-18 | 2.32e-16 | 1.70e-16 | 137 |
hsa04723110 | Endometrium | AEH | Retrograde endocannabinoid signaling | 39/1197 | 148/8465 | 5.89e-05 | 5.80e-04 | 4.24e-04 | 39 |
hsa0501227 | Endometrium | EEC | Parkinson disease | 117/1237 | 266/8465 | 5.97e-32 | 9.82e-30 | 7.32e-30 | 117 |
hsa0501625 | Endometrium | EEC | Huntington disease | 120/1237 | 306/8465 | 3.86e-27 | 4.23e-25 | 3.15e-25 | 120 |
hsa0502025 | Endometrium | EEC | Prion disease | 111/1237 | 273/8465 | 1.01e-26 | 8.27e-25 | 6.16e-25 | 111 |
hsa0019025 | Endometrium | EEC | Oxidative phosphorylation | 70/1237 | 134/8465 | 6.33e-25 | 3.47e-23 | 2.59e-23 | 70 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NDUFB10 | SNV | Missense_Mutation | novel | c.94N>A | p.Asp32Asn | p.D32N | O96000 | protein_coding | tolerated(0.43) | benign(0.001) | TCGA-BH-A42V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NDUFB10 | SNV | Missense_Mutation | c.385G>A | p.Val129Met | p.V129M | O96000 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
NDUFB10 | SNV | Missense_Mutation | c.81G>A | p.Met27Ile | p.M27I | O96000 | protein_coding | tolerated(0.44) | benign(0) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
NDUFB10 | deletion | Frame_Shift_Del | c.84delG | p.Met28IlefsTer12 | p.M28Ifs*12 | O96000 | protein_coding | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |||
NDUFB10 | SNV | Missense_Mutation | c.461N>A | p.Arg154Lys | p.R154K | O96000 | protein_coding | tolerated(1) | benign(0) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
NDUFB10 | SNV | Missense_Mutation | novel | c.163N>C | p.Tyr55His | p.Y55H | O96000 | protein_coding | tolerated(0.09) | possibly_damaging(0.83) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
NDUFB10 | SNV | Missense_Mutation | c.295N>G | p.Ile99Val | p.I99V | O96000 | protein_coding | tolerated(0.24) | benign(0.062) | TCGA-CK-6748-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
NDUFB10 | SNV | Missense_Mutation | c.211N>C | p.Cys71Arg | p.C71R | O96000 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
NDUFB10 | SNV | Missense_Mutation | rs149920175 | c.191G>A | p.Arg64His | p.R64H | O96000 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-AJ-A3NE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NDUFB10 | SNV | Missense_Mutation | rs140580390 | c.277G>A | p.Asp93Asn | p.D93N | O96000 | protein_coding | deleterious(0.05) | probably_damaging(0.999) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4716 | NDUFB10 | ENZYME | inhibitor | CHEMBL3545320 | ME-344 | |
4716 | NDUFB10 | ENZYME | inhibitor | CHEMBL1703 | METFORMIN HYDROCHLORIDE | |
4716 | NDUFB10 | ENZYME | inhibitor | CHEMBL3545135 | NV-128 |
Page: 1 |